kabutan

GNI Group Ltd.(2160) Summary

2160
TSE Growth
GNI Group Ltd.
2,967
JPY
-198
(-6.26%)
Apr 30, 10:16 am JST
18.51
USD
Apr 29, 9:16 pm EDT
Result
PTS
outside of trading hours
2,961.2
Apr 30, 10:15 am JST
Summary Chart Historical News Financial Result
PER
PBR
3.29
Yield
ー%
Margin Trading Ratio
41.51
Stock Price
Apr 30, 2026
Opening Apr 30, 9:03 am
3,050 JPY 19.04 USD
Previous Close Apr 28
3,165 JPY 19.88 USD
High Apr 30, 9:03 am
3,055 JPY 19.07 USD
Low Apr 30, 9:16 am
2,951 JPY 18.41 USD
Volume
740,800
Trading Value
2.22B JPY 0.01B USD
VWAP
2993.34 JPY 18.68 USD
Minimum Trading Value
296,700 JPY 1,851 USD
Market Cap
0.17T JPY 1.03B USD
Number of Trades
1,418
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
High
1-Year Average
3,407
1-Year High May 27, 2025
36,454
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 602,200 7,220,700 11.99
Apr 17, 2026 623,600 7,098,400 11.38
Apr 10, 2026 615,600 7,142,400 11.60
Apr 3, 2026 596,300 7,120,500 11.94
Mar 27, 2026 618,700 7,690,000 12.43
Company Profile
GNI Group Ltd. is a biotech venture company focused on drug discovery. It has research and development centers in the United States and China. The company's main product is a drug for idiopathic pulmonary fibrosis. They are also involved in genetic analysis.
Sector
Pharmaceuticals
GNI Group Ltd. operates in both the pharmaceutical and medical device sectors. In its pharmaceutical business, the company sells F351 (Etuary), a treatment for fibrosis, in the Chinese market. They also conduct research, development, manufacturing, and sales of drug compounds targeting lung diseases (interstitial lung diseases), liver diseases, and kidney diseases (chronic kidney disease). The medical device business is based in the United States and focuses on the development, manufacturing, and sales of biomaterials. The group consists of the parent company, 18 consolidated subsidiaries, and 2 affiliated companies. They also provide services such as reagents, designated manufacturing and marketing of medical devices, and domestic clinical trial management.